[go: up one dir, main page]

HUE067188T2 - Piridazinonok és azok felhasználási eljárásai - Google Patents

Piridazinonok és azok felhasználási eljárásai

Info

Publication number
HUE067188T2
HUE067188T2 HUE19863481A HUE19863481A HUE067188T2 HU E067188 T2 HUE067188 T2 HU E067188T2 HU E19863481 A HUE19863481 A HU E19863481A HU E19863481 A HUE19863481 A HU E19863481A HU E067188 T2 HUE067188 T2 HU E067188T2
Authority
HU
Hungary
Prior art keywords
pyridazinones
methods
Prior art date
Application number
HUE19863481A
Other languages
English (en)
Inventor
Mark Ledeboer
Matthew Daniels
Maolin Yu
Jean-Christophe Harmange
Original Assignee
Gfb Abc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gfb Abc Llc filed Critical Gfb Abc Llc
Publication of HUE067188T2 publication Critical patent/HUE067188T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE19863481A 2018-09-18 2019-09-18 Piridazinonok és azok felhasználási eljárásai HUE067188T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732728P 2018-09-18 2018-09-18
US201862780553P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
HUE067188T2 true HUE067188T2 (hu) 2024-10-28

Family

ID=69887813

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19863481A HUE067188T2 (hu) 2018-09-18 2019-09-18 Piridazinonok és azok felhasználási eljárásai

Country Status (32)

Country Link
US (3) US10654850B2 (hu)
EP (2) EP3852533B8 (hu)
JP (2) JP7474243B2 (hu)
KR (1) KR20210069652A (hu)
CN (1) CN112911935A (hu)
AU (1) AU2019344928A1 (hu)
BR (1) BR112021004926A2 (hu)
CA (1) CA3113236A1 (hu)
CL (1) CL2021000648A1 (hu)
CO (1) CO2021004789A2 (hu)
DK (1) DK3852533T3 (hu)
EC (1) ECSP21026485A (hu)
ES (1) ES2982498T3 (hu)
FI (1) FI3852533T3 (hu)
HR (1) HRP20240707T1 (hu)
HU (1) HUE067188T2 (hu)
IL (1) IL281438B2 (hu)
LT (1) LT3852533T (hu)
MD (1) MD3852533T2 (hu)
MX (1) MX2021003152A (hu)
PE (2) PE20211774A1 (hu)
PH (1) PH12021550443A1 (hu)
PL (1) PL3852533T3 (hu)
PT (1) PT3852533T (hu)
RS (1) RS65558B1 (hu)
SG (1) SG11202102053VA (hu)
SI (1) SI3852533T1 (hu)
SM (1) SMT202400201T1 (hu)
TW (2) TW202430524A (hu)
UA (1) UA128841C2 (hu)
UY (1) UY38377A (hu)
WO (1) WO2020061162A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38377A (es) 2018-09-18 2020-04-30 Goldfinch Bio Inc Piridazinonas y sus métodos de uso
MA55381A (fr) * 2019-03-20 2022-01-26 Goldfinch Bio Inc Pyridazinones et leurs procédés d'utilisation
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
AU2020273174A1 (en) 2019-04-11 2021-11-18 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
KR20220079907A (ko) * 2019-10-04 2022-06-14 골드핀치 바이오 인코포레이티드 국소분절사구체경화증 및 당뇨병성 신장 질환의 바이오마커 기반 치료
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
CN113880843B (zh) * 2020-07-03 2023-03-10 武汉朗来科技发展有限公司 一种杂环化合物及其应用
CN114907408B (zh) * 2021-02-07 2024-05-03 武汉朗来科技发展有限公司 一种杂环化合物、其中间体、其制备方法及其应用
EP4400500A1 (en) * 2021-09-10 2024-07-17 Medshine Discovery Inc. Halogen-substituted pyridazinone compound and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
AU2005206562A1 (en) * 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP4705922B2 (ja) 2004-01-29 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
DE102004044231A1 (de) 2004-09-14 2006-03-16 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
DE602005010463D1 (de) 2004-10-13 2008-11-27 Merck & Co Inc Cgrp-rezeptorantagonisten
EP2069312B1 (en) 2006-07-25 2012-11-07 Cephalon, Inc. Pyridizinone derivatives
EP2136808A2 (en) 2007-03-15 2009-12-30 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
CN101842359A (zh) * 2007-10-31 2010-09-22 日产化学工业株式会社 哒嗪酮化合物和p2x7受体抑制剂
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
KR101864908B1 (ko) * 2010-09-01 2018-06-05 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
CA2874953A1 (en) * 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP6667093B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2019055966A2 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
UY38377A (es) 2018-09-18 2020-04-30 Goldfinch Bio Inc Piridazinonas y sus métodos de uso
MA55381A (fr) * 2019-03-20 2022-01-26 Goldfinch Bio Inc Pyridazinones et leurs procédés d'utilisation
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
AU2020273174A1 (en) * 2019-04-11 2021-11-18 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
KR20220079907A (ko) * 2019-10-04 2022-06-14 골드핀치 바이오 인코포레이티드 국소분절사구체경화증 및 당뇨병성 신장 질환의 바이오마커 기반 치료

Also Published As

Publication number Publication date
EP3852533A4 (en) 2022-06-15
MD3852533T2 (ro) 2024-08-31
FI3852533T3 (fi) 2024-05-24
JP2024099595A (ja) 2024-07-25
US10654850B2 (en) 2020-05-19
ES2982498T3 (es) 2024-10-16
SMT202400201T1 (it) 2024-07-09
IL281438B2 (en) 2023-12-01
PE20250453A1 (es) 2025-02-19
TWI828758B (zh) 2024-01-11
WO2020061162A1 (en) 2020-03-26
SI3852533T1 (sl) 2024-10-30
TW202430524A (zh) 2024-08-01
RS65558B1 (sr) 2024-06-28
UY38377A (es) 2020-04-30
HRP20240707T1 (hr) 2024-10-11
US11046690B2 (en) 2021-06-29
US20220024917A1 (en) 2022-01-27
US20200102301A1 (en) 2020-04-02
US20200283437A1 (en) 2020-09-10
CN112911935A (zh) 2021-06-04
BR112021004926A2 (pt) 2021-06-01
DK3852533T3 (da) 2024-05-27
PH12021550443A1 (en) 2021-12-06
PE20211774A1 (es) 2021-09-08
PT3852533T (pt) 2024-05-31
JP7474243B2 (ja) 2024-04-24
CL2021000648A1 (es) 2021-08-06
IL281438A (en) 2021-04-29
AU2019344928A1 (en) 2021-04-29
ECSP21026485A (es) 2021-07-30
EP3852533B8 (en) 2024-07-17
TW202035402A (zh) 2020-10-01
MX2021003152A (es) 2021-06-23
IL281438B1 (en) 2023-08-01
EP3852533A1 (en) 2021-07-28
CO2021004789A2 (es) 2021-07-30
KR20210069652A (ko) 2021-06-11
SG11202102053VA (en) 2021-04-29
PL3852533T3 (pl) 2024-09-16
EP4414365A1 (en) 2024-08-14
CA3113236A1 (en) 2020-03-26
UA128841C2 (uk) 2024-11-06
EP3852533B1 (en) 2024-02-28
JP2022500359A (ja) 2022-01-04
LT3852533T (lt) 2024-06-10

Similar Documents

Publication Publication Date Title
EP3684364A4 (en) PYRIDAZINONE AND METHOD OF USE THEREOF
IL281438A (en) Pyridazinones and methods of using them
IL281445A (en) Therapeutic nanoparticles and methods for their use
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL280709A (en) Converted indoles and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
IL286481A (en) Pyridazinones and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL276687A (en) Trialkyne coupling agents and methods of using them
IL283782A (en) Analosomes and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL318324A (en) Devices and methods of introduction into the body and their use
ZA202005674B (en) Glucoamylases and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL265881A (en) Inhaler and methods of use thereof
IL276135A (en) Preparations and methods of use
IL276053A (en) Therapeutic Gard and methods of its use
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
IL280000A (en) Formulations for reducing tumors and methods of using them
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
IL283231A (en) dpep-1 binding factors and methods of use
IL276792A (en) Inhaler and methods for using it
IL281865A (en) Instruments and methods for income and use
GB202009064D0 (en) Compounds and methods of use
GB201709186D0 (en) Construction block and methods of use